Condition or disease | Intervention/treatment |
---|---|
Adenomyosis Endometrial Cancer Ectopic Endometrial Tissue Eutopic Endometrium Genomics Transcriptomics | Genetic: whole exome sequencing and RNA-sequencing |
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Observational Model: | Case-Control |
Time Perspective: | Retrospective |
Official Title: | A Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis |
Actual Study Start Date : | July 16, 2019 |
Estimated Primary Completion Date : | August 1, 2021 |
Estimated Study Completion Date : | August 1, 2021 |
Group/Cohort | Intervention/treatment |
---|---|
Endometrial carcinoma arising in adenomyosis
Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
|
Genetic: whole exome sequencing and RNA-sequencing
The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
|
Adenomyosis without malignancy
Patients pathologically diagnosed with adenomyosis
|
Genetic: whole exome sequencing and RNA-sequencing
The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Study population includes two groups patients (about 22 cases in each group):
Inclusion Criteria:
Exclusion Criteria:
Contact: Lei Li, M.D. | +8613911988831 | lileigh@163.com |
China, Beijing | |
Lei Li | Recruiting |
Beijing, Beijing, China, 100730 | |
Contact: Lei Li, MD 008613911988831 lileigh@163.com |
Principal Investigator: | Lei Li, M.D. | Peking Union Medical College Hospital |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | July 3, 2019 | ||||
First Posted Date | July 8, 2019 | ||||
Last Update Posted Date | July 18, 2019 | ||||
Actual Study Start Date | July 16, 2019 | ||||
Estimated Primary Completion Date | August 1, 2021 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures | Not Provided | ||||
Original Secondary Outcome Measures | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis | ||||
Official Title | A Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis | ||||
Brief Summary | This study is to explore the driving genes and the molecular mechanism of malignant transformation of adenomyosis. This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA) treated at Peking Union Medical College Hospital from July 15, 2017 to July 15, 2019. The formalin fixed paraffin-embedded tissues from patients pathologically diagnosed with adenomyosis during this time period were also included as control specimens. The eutopic endometrium, normal adenomyosis tissue, and EC-AIA tissue were harvested from the FFPE tissue from patients with EC-AIA. The normal eutopic endometrium and normal adenomyosis tissue were obtained by laser microdissection. The driving genes and potential molecular mechanism of EC-AIA will be found by the technology of whole exome sequencing and transcriptomics (RNA-sequencing). | ||||
Detailed Description | Not Provided | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Control Time Perspective: Retrospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Retention: Samples With DNA Description:
This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA) treated at Peking Union Medical College Hospital from July 15, 2017 to July 15, 2019. The formalin fixed paraffin-embedded tissues from patients pathologically diagnosed with adenomyosis during this time period were also included as control specimens.
|
||||
Sampling Method | Non-Probability Sample | ||||
Study Population |
Study population includes two groups patients (about 22 cases in each group):
|
||||
Condition |
|
||||
Intervention | Genetic: whole exome sequencing and RNA-sequencing
The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
40 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | August 1, 2021 | ||||
Estimated Primary Completion Date | August 1, 2021 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts |
|
||||
Listed Location Countries | China | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04010487 | ||||
Other Study ID Numbers | AM-OMICS2 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Responsible Party | Lei Li, Peking Union Medical College Hospital | ||||
Study Sponsor | Lei Li | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | Peking Union Medical College Hospital | ||||
Verification Date | July 2019 |